Search

High-grade astrocytomas (HGAs) are the most common adult primary malignant brain tumor, which include anaplastic astrocytoma (AA; World Health Organization [WHO] grade III) and glioblastoma multiforme (GBM; WHO grade IV). Although HGAs represent an overall uncommon cancer, they are associated with morbidity and high mortality. Despite state-of-the-art multimodality treatments, the median survival of GBM patients is 12–15 months, whereas that of AA is 2–3 years [1]. Current treatments for HGA include surgery, radiation, and chemotherapy. Temozolomide, an oral alkylating chemotherapy, has been approved for newly diagnosed GBM and recurrent AA. It offers significant, albeit modest, survival benefit for unselected HGA patients. [ABSTRACT FROM AUTHOR]